San Francisco, October 17, 2018 – Recardio Inc. presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2018 in San Francisco.
Recardio presents at the 2018 Annual Meeting of the European Society of Cardiology in Munich
San Francisco, August 25, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Chief Scientific Officer, Darrell Nix, Ph.D., presented today the findings of a Phase 1 study of its lead drug candidate dutogliptin for the treatment of patients in early recovery post-myocardial infarction.
Recardio expands Management Board
San Francisco, June 28th,2018 – Recardio Inc. today announced that it has expanded its Management Board, reflecting the companies expansion of clinical development in 2018.
Recardio initiates patient recruitment for Phase 2 Study Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
San Francisco, May 28, 2018 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it is starting recruiting patients for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Recruitment for this randomized, double-blind, placebo-controlled trial will begin in one of the 29 participating trial centers in the European Union and be expanded rapidly to also include 5 centers in the United States.
Recardio receives FDA approval for Phase 2 Study
San Francisco, January 31st, 2018 – Recardio Inc. today announced that it has received the FDA approval for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.